Emerging Med Tech
The question is not whether organoids or bioprinted tissues can form vessels. It's whether engineered vascular systems can sustain organ-level perfusion, host anastomosis, hierarchical architecture, function, immune compatibility, scale, and regulatory-grade safety.
Clinical-Grade Liver & Kidney Biofabrication
- DOSSIERAcross vascularized organoids, 3D-bioprinted constructs, microfluidics and bioreactors, for both liver and kidney.
- WORKBOOK17 sheets. 44 claims with verbatim excerpts; a GMP translation roadmap and regulatory pathfinding.
- AUDITRelease-ready. Every citation re-verified live, zero retractions.
- HYPOTHESESFalsifiable validation hypotheses tied to the binding technical gates.
Exactly what's inside Clinical-Grade Liver & Kidney Biofabrication.
The full research-report table of contents and every one of the 17 tables in the evidence workbook — the real structure of what you license, not a teaser.
- Report Scope and Evidence Integrity Statement
- 2026 Translational Signal Update
- Executive Summary
- Decision Snapshot
- Buyer Decision Cheat Sheet
- Source Quality Dashboard
- Evidence Maturity Matrix
- Platform Comparison
- Liver vs Kidney Translation Framework
- Key Findings and Quantitative Evidence
- Mechanistic Insights
- Safety, Immunogenicity, and Host-Integration Risks
- Manufacturing, GMP, and CMC Readiness
- Regulatory Pathway and Classification Issues
- Company / Platform / Funding Landscape
- Most Valuable Next Studies
- Validation and Falsification Gate Map
- Strategic Recommendations
- Final Judgment
- Expert Review and Validation Attestation
- Source Audit Summary
- Appendix: Methods and Workbook Guide
- References (Vancouver)
Workbook Guide
An orientation to the workbook — its scope, how the claim counts reconcile, and the audit posture.
In this dossier: Buyer-auditable evidence asset accompanying the dossier 'Toward Clinical-Grade Liver and Kidney Biofabrication'. Every customer-facing claim is traceable to a source and…
Claim Ledger
Every factual claim in the report, independently re-verified against its primary source, each carrying a support verdict and a recalibrated evidence grade.
In this dossier: 42 customer-facing claims drawn from the kept set of a 179-claim audit. Evidence grades reflect an external GRADE-style re-review (study design, journal, functional…
Evidence Table
The full registry of cited sources — PMIDs, NCTs and DOIs — with metadata, resolved live against the primary record.
In this dossier: Primary studies, authoritative reviews, and registry entries underpinning the dossier, including the 2026 refresh sources. Open the URL to verify each item.
Source Support Verdicts
The verbatim source excerpt behind each claim, with an independent verdict on whether the source actually supports it.
In this dossier: Adjudication of how well each cited source supports the claim it underpins. Categories: SUPPORTS_EXACTLY, SUPPORTS_PARTIALLY, SOURCE_EXISTS_BUT_DOES_NOT_SUPPORT…
Source Quality Summary
A reconciled view of source quality across the evidence base, with the grading rationale.
In this dossier: Reconciles the customer-facing claim pool with the full audit. GRADE counts below are computed directly from the Claim Ledger's external re-review, so the Claim Ledger…
Platform Scorecard
Programs or modalities scored on the framework's axes — a structured, side-by-side comparison (expert, ordinal, non-evidentiary).
In this dossier: Eleven platforms scored 0-4 across seven maturity dimensions (drives Figures 1 and 3). 0=none 1=concept 2=in vitro 3=preclinical 4=robust/validated.
Liver vs Kidney
A structured table within the evidence workbook.
In this dossier: Why the liver path (temporary support) is nearer-term than the kidney path (functional replacement).
Figure Source Map
The provenance of every figure — its underlying data and how it was produced.
In this dossier: Provenance of every figure: the claims and sources it draws on, the data fields used, and any missing fields. Claim IDs are auto-resolved from the cited sources.
Figure Attempt Ledger
The provenance of every figure — its underlying data and how it was produced.
In this dossier: Publishability status of all 17 figures. No figure is PENDING. Statuses: PASS, PASS_WITH_LIMITATIONS, CONCEPT_ONLY, INELIGIBLE, FAIL.
Next Studies
The highest-leverage experiments to run next, prioritized — a ready-made research agenda.
In this dossier: Ten specific, falsifiable studies with endpoints, success/failure criteria, timeline, cost tier, and buyer implication.
Validation Gates
A structured table within the evidence workbook.
In this dossier: Six binary, falsifiable translational gates. All gates are OPEN as of the 2026 evidence window.
CMC Risk Matrix
A structured map across this dimension of the analysis.
In this dossier: Eight CMC platforms scored 0-4 across eleven manufacturing dimensions (drives Figures 11-12). Vascular potency assay is uniformly absent — the decisive CMC gap.
Regulatory Tracker
Regulatory designations and pathways relevant to each program — noting that a designation is never an approval.
In this dossier: Classification logic and IND-enabling requirements. No defined FDA/EMA pathway exists for this construct class; entries are requirements/analogies, not approvals.
Company-Funding Tracker
A structured tracker of the programs, signals and evidence in this dimension of the analysis.
In this dossier: Key academic performers, companies, and funders. Program signals are verified via the 2026 refresh.
Trial-Registry Tracker
A structured tracker of the programs, signals and evidence in this dimension of the analysis.
In this dossier: Registry sweep (Jun 2026). No registered interventional trial of a bioprinted/organoid liver or kidney CONSTRUCT transplant. Adjacent entries are listed for context.
2026 Update Sources
A structured table within the evidence workbook.
In this dossier: Targeted 2026 refresh. Each row: source, claim, verification status, thesis impact, and whether it upgrades / downgrades / does not change the thesis.
Expert Review & Validation
A structured table within the evidence workbook.
In this dossier: Methodology, reviewer roles, and attestation. The dossier was reviewed and validated by an AI domain-expert agent specialized in perfusable vascular networks — the…
Click any table to see what it is.
Different buyers live in different tabs.
Click a buyer to see exactly what they get.
Every claim resolves to a primary source.
This dossier ships with its independent diligence audit. Evidence is labelled Established / Inferred / Hypothesis. A surrogate is never equated with outcome; a designation is never an approval.
Zemi Research publishes independent, pre-packaged research reports delivered as digital downloads (PDF + spreadsheet). These are information products — not medical, clinical, investment, legal, or professional advice; not a consulting, advisory, or regulated service; and they create no professional-client relationship. Provided for general informational use by industry professionals.